ODM derived from

  1. 2013-12-11 2013-12-11 - Martin Dugas
  2. 2014-04-14 2014-04-14 - Julian Varghese
  3. 2021-04-13 2021-04-13 - Dr. rer. medic Philipp Neuhaus
  4. 2021-09-20 2021-09-20 -
Uppladdad den:

20 september 2021

För en begäran logga in.
Licens :
Creative Commons BY 4.0
Modellkommentarer :

Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.

Itemgroup-kommentar för :

Item-kommentar för :

Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.

Eligibility DRKS00003823 NCT00478777 Relapsed or Refractory Multiple Myeloma


  1. StudyEvent: Eligibility
    1. Eligibility
Alter mindestens 18 Jahre
Must understand and voluntarily sign an informed consent form.
Must be >=18 years of age at the time of signing the informed consent form.
Must be able to adhere to the study visit schedule and other protocol requirements.
Must be diagnosed with multiple myeloma that is progressing after at least 2 cycles of anti-myeloma treatment or that has relapsed with progressive disease after treatment.
Subjects may have been previously treated with thalidomide and/or radiation therapy. In addition, radiation therapy initiated prior to or at baseline (Day 1) may be given concurrently with study therapy, provided that all other eligibility criteria are satisfied.
Subjects must discontinue all anti-myeloma drug or non-drug therapy prior to the first dose of study drug with the exception of radiation therapy initiated prior to or at baseline (Day 1).
Measurable levels of myeloma paraprotein in serum (>0.5 g/dL) or urine (>0.2 g excreted in a 24-hour collection sample).
ECOG Status <= 2
The presence of any of the following will exclude a subject from study enrollment:
Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.
Pregnant or lactating females.
Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
Any of the following laboratory abnormalities:
Absolute Neutrophil Count
Platelet count <75,000/mm^3 (75 x 109/L) for subjects in whom <50% of the bone marrow nucleated cells are plasma cells.
Platelet count <30,000/mm^3 (30x10^9/L) for subjects in whom >=50% of bone marrow nucleated cells are plasma cells.
Kreatinin im Serum
Serum SGOT/AST or SGPT/ALT >3.0 x upper limit of normal (ULN)
Serum Total Bilirubin Measurement
Prior history of malignancies other than multiple myeloma (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast) unless the subject has been free of the disease for >=1 year.
Prior history of stroke and/or thromboembolic event
Known hypersensitivity to thalidomide or dexamethasone.
Prior history of uncontrollable side effects to dexamethasone therapy.
The development of a desquamating rash while taking thalidomide.
Neuropathy >= Grade 2.

Similar models

Använd detta formulär för feedback, frågor och förslag på förbättringar.

Fält markerade med * är obligatoriska.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial